On the directive of President Ferdinand R. Marcos Jr., the Food and Drug Administration (FDA) is set to shorten the period of review and approval processes of applications of generic drugs from 120 days down to only 45 days. “I’m on the verge of signing the memorandum circular for the facilitation of FRP for generic drug – it means it …
Read More »
The Market Monitor Minding the Nation's Business